TNFRSF11B and diabetes mellitus: The OPG and RUNX 2 positive-staining area increased (CS vs. diabetes, p < 0.01, Met vs. diabetes, p < 0.01) and the RANKL positive-staining area decreased after CS or metformin treatment (CS vs. diabetes, p < 0.01, Met vs. diabetes, p < 0.01).